首款三价HPV疫苗要来了

Core Viewpoint - The three-valent HPV vaccine developed by Kangla Weishi has received acceptance for market application, marking the first three-valent HPV vaccine application in China aimed at preventing HPV 16/18/58 related persistent infections and cervical cancer [1] Group 1 - The vaccine is specifically designed to prevent diseases associated with HPV types 16, 18, and 58 [1] - This development represents a significant milestone in the domestic vaccine market, particularly in the context of HPV prevention [1]